Novo Nordisk A/S $NVO Shares Purchased by Potomac Fund Management Inc. ADV

Potomac Fund Management Inc. ADV increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 66.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,510 shares of the company’s stock after purchasing an additional 13,033 shares during the period. Potomac Fund Management Inc. ADV’s holdings in Novo Nordisk A/S were worth $1,654,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of NVO. Revolve Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. Invesco Ltd. raised its holdings in Novo Nordisk A/S by 26.3% in the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after acquiring an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at $314,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NVO. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $43.90 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a 50-day moving average of $42.28 and a two-hundred day moving average of $46.00. The stock has a market cap of $196.02 billion, a P/E ratio of 10.31, a PEG ratio of 3.92 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, research analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.